Balyasny Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Balyasny Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-121,723	Closed	-$6.2M	–	2942
2021 Q4	$6.2M	Sell	121,723 -43,571	-26%	-$2.26M	0.02%	780
2021 Q3	$9.22M	Buy	+165,294	New	+$8.13M	0.04%	611
2019 Q1	–	Sell	-28,633	Closed	-$1.15M	–	1714
2018 Q4	$1.15M	Buy	+28,633	New	+$1.48M	0.01%	856
2015 Q3	–	Sell	-7,055	Closed	-$570K	–	1438
2015 Q2	$570K	Buy	+7,055	New	+$460K	﹤0.01%	842

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's EGRX Position: Q1 2022 in Review

Balyasny Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 121,723 shares — an estimated $6.2M sold.

Balyasny Asset Management first reported a position in EGRX in Q2 2015 and held it in 4 quarters. The position peaked at $9.22M in Q3 2021. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

Balyasny Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Balyasny Asset Management sold 121,723 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $6.2M.
Balyasny Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 4 quarters.
Balyasny Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $9.22M in Q3 2021.
160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Balyasny Asset Management's 13F filing for Q1 2022, filed 16 May 2022.